Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
This issue brief provides a snapshot of current state initiatives aimed at addressing the cost of prescription drugs in Medicaid.
View the Latest: Prescription Drugs
Filter
-
-
Summary of Recent and Proposed Changes to Medicare Prescription Drug Coverage and Reimbursement
Issue BriefOn February 9, 2018 the President signed into law the Bipartisan Budget Act of 2018, which included some provisions related to Medicare Part D prescription drug coverage. Shortly thereafter, the Office of Management and Budget released the President’s fiscal year (FY) 2019 budget, which also included several proposals related to Medicare Part D drug coverage and Part B drug reimbursement. This brief summarizes these recently enacted and proposed changes.
-
Insulin Costs and Coverage in Medicare Part D
Issue BriefIn light of heightened attention to insulin and the Trump Administration’s new Part D model to address out-of-pocket costs for insulin for Medicare beneficiaries, we analyzed out-of-pocket spending on insulin by beneficiaries enrolled in Part D drug plans, variation in Part D plan formulary coverage and tier placement of insulin products, and trends in prices for insulin.
-
State Medicaid Management of Prescription Drugs for HIV Treatment and Prevention
Issue BriefThis data note, primarily based on a survey of state Medicaid pharmacies, reviews cost-containment policies and protections as they relate to antiretrovirals for treatment and prevention of HIV.
-
Poll: Two-thirds of Voters Say a Candidate’s Position on Pre-existing Conditions is Important to their Vote, More than Say the Same about Drug Costs, ACA Repeal or Medicare-for-All
News ReleaseAbout two-thirds (65%) of voters say a candidate’s support for continued protections for people with pre-existing health conditions is either the “single most important factor” or “very important” to their vote in the upcoming midterms elections, finds the latest Kaiser Family Foundation tracking poll.
-
Kaiser Health Tracking Poll – June 2018: Campaigns, Pre-Existing Conditions, and Prescription Drug Ads
FeatureThe June 2018 KFF Tracking Poll examines the top issues voters want to hear candidates talk about during their 2018 congressional campaigns, including the importance of specific health care positions such as continuing protections for people with pre-existing conditions. The Kaiser poll also examines the public’s views and experiences with prescription drug advertisements and pricing.
-
What’s in the Administration’s 5-Part Plan for Medicare Part D and What Would it Mean for Beneficiaries and Program Savings?
Issue BriefWith rising concern over increases in prescription drug costs, the Trump Administration has proposed what it calls a “5-part plan” that would change several features of the Medicare Part D drug benefit. This brief describes the Administration’s five Part D proposals and discusses the potential implications for people with Part D prescription drug coverage and Medicare program spending, based on estimates from the Congressional Budget Office.
-
How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid?
Issue BriefThis issue brief examines how the Trump Administration proposals to lower drug costs described in the Administration's Blueprint affect Medicaid. These include proposals to change the Medicaid Drug Rebate Program, as well as other approaches.
-
Drug costs are a problem for a greater share of women than men
FeatureSource 2017 Kaiser Women's Health Survey…
-
Three firms Account for Over Half of All Medicare Part D Enrollees in 2018, and Pending Mergers Would Further Consolidate the Marketplace
News ReleaseIn 2018, three Medicare Part D plan sponsors—UnitedHealth, Humana, and CVS Health—account for more than half of the program’s 43 million Part D enrollees (55%) and two-thirds of all stand-alone drug plan enrollees, indicating a marketplace that is dominated by a handful of major insurers, according to a new Kaiser Family Foundation analysis of Part…